RGN Regenerx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the “Company” or “RegeneRx”) today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx’s ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline. Corneal fluorescein staining was used to measure the surface defects after induction of DES using an industry accepted dry eye model. In animals treated with RGN-259, a “dramatic” and statistically significant reduction in corneal staining (p

Regenerx Biopharm In (AMEX:RGN)
過去 株価チャート
から 5 2024 まで 6 2024

Regenerx Biopharm In (AMEX:RGN)
過去 株価チャート
から 6 2023 まで 6 2024